Table 1 Tuberculosis vaccine candidates in clinical trials

Subunit – protein in adjuvant

M72/AS01

Phase IIb

NCT01098474 (Phase II)

Fusion protein (Mtb39a, Mtb32a) in AS01 adjuvant

H1/IC31

Phase IIa

Fusion protein (Ag85B, ESAT-6) in IC31 adjuvant

H4/IC31

Phase II

NCT01861730 (Phase I/II)

Fusion protein (Ag85B, TB10.4) in IC31 adjuvant

H56/IC31

Phase IIa

Fusion protein (Ag85B, ESAT-6, Rv2660c) in IC31 adjuvant

ID93/GLA-SE

Phase I

Fusion protein (Rv3619, Rv1813c, Rv3620c, Rv2608) in GLA-SE adjuvant

Subunit – viral vectors

MVA85A

Phase IIb

NCT00953927 (Phase IIb)

Replication-deficient vaccinia Ankara virus expressing Ag85A

Ad5Ag85A

Replication-deficient adenovirus-5 expressing Ag85A

AD35.TB-S

NCT01198366 (Phase II)

Replication-defective adenovirus-35 expressing Ag85A, Ag85B, TB10.4

Recombinant BCG

rBCG30

Phase I (discontinued)

Recombinant BCG over-expressing Ag85B

VPM1002

Phase IIa

NCT01479972 (Phase I) NCT02391415 (Phase IIa)

Recombinant BCG deleted of ureC gene and expressing L. monocytogenes LLO

AERAS-422

Phase I (discontinued)

Recombinant BCG expressing Ag85A, Ag85B, Rv3407

Attenuated M. tuberculosis

MTBVAC

Phase IIa

NCT02729571 (Phase I)

Live attenuated M. tuberculosis deleted of phoP and fadD26 genes

Inactivated Mycobacteria

Dar-901

Phase I

Heat-inactivated Mycobacterium obuense